Emerging studies suggest Retatrutide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , appears to provide a promising advancement for body loss . Early human tests have demonstrated substantial decreases in visceral fat , conceivably outperforming other body composition medications . However , fur